Look beyond drug makers to avoid tragedies like meningitis outbreak, expert says

October 17, 2012 by Elizabeth K. Gardner

(Medical Xpress)—A Purdue University medication safety expert said it is important to look at the larger system surrounding medication use, as well as the facilities where drugs are made to avoid tragedies like the meningitis outbreak that has claimed 15 lives.

"No one condones making a bad product, but we also need to examine the quality assurance process of the larger medication-use system that doesn't catch it," said John B. Hertig, project manager for the Purdue College of Pharmacy's Center for Medication Safety Advancement. "It is a failure of the larger system and practices that allow a harmful product to make it through numerous hands and be administered to a patient. A system-wide view is the most effective in improving overall ."

The broader pharmaceutical system can be thought of as a stack of slices of Swiss cheese, Hertig said. Each step in the system, from manufacture to shipping and receiving to treatment, has holes where a mistake could go undetected. It is only when the holes in each piece line up that a mistake can make it all the way through to a patient, he said.

The recently linked a meningitis outbreak that spans 15 states to possibly tainted that were made in a Massachusetts facility. The on Monday (Oct. 15) reported 212 people have been infected and 14,000 may have received the injections.

The outbreak raises questions about the oversight of such facilities, called compounding pharmacies, which create customized medication solutions for patients for whom manufactured drugs won't work or are not available, Hertig said.

"In the midst of tragedy our emotions run high and we can get caught up in putting all of the blame on an individual," he said. "We certainly shouldn't tolerate gross negligence, but we also need to take a step back and look at the bigger picture. Even after the individuals responsible for a particular incident have been held accountable, unaddressed flaws in the system will continue to produce negative consequences."

Hertig also is concerned that over-regulation of compounding pharmacies could have the unintended consequence of adding significant costs to the facilities, raising the prices of such treatments and shrinking a critical source of pharmaceuticals.

There have been 200 instances of harmful side effects or illnesses caused by treatments involving 71 compounded products reported to the Food and Drug Administration since 1990, Hertig said.

"It is important to note that these cases represent a very small fraction of the total number of compounded medications dispensed, and without these pharmacies many patients would not have access to much-needed therapies," he said. "Greater regulation may be part of the solution, but enacting increasingly complicated legislation could inhibit compounding pharmacies to the detriment of patient care."

Explore further: Official: pharmacy tied to meningitis outbreak may have broken state law

Related Stories

Official: pharmacy tied to meningitis outbreak may have broken state law

October 12, 2012
(HealthDay)—The company at the center of the ongoing meningitis outbreak appears to have violated Massachusetts law by producing and distributing large quantities of a contaminated steroid compound, a state health official ...

Experts list many ways funguses can taint drugs

October 16, 2012
(AP)—Experts say there are many ways funguses could have gotten inside the Massachusetts pharmacy at the center of the deadly U.S. outbreak of fungal meningitis.

US clinics rush to warn of tainted steroid; 5 dead

October 5, 2012
(AP)—Health providers scrambled to notify patients in nearly two dozen U.S. states that the steroid injections they received for back pain may have been contaminated with a deadly fungal meningitis. Five people have died.

Tainted drug death toll rises to 14 in US

October 11, 2012
The death toll from a deadly meningitis outbreak in the United States blamed on a tainted drug rose to 14 Thursday as the number of cases jumped to 172 in 11 states, health officials said.

US: Avoid drugs from company tied to meningitis (Update)

October 4, 2012
U.S. health officials ramped up warnings Thursday about a specialty pharmacy linked to a widening outbreak of a rare kind of meningitis, urging doctors and hospitals not to use any products from the company.

Calls for more US oversight after tainted drug outbreak

October 11, 2012
A deadly meningitis outbreak in the United States blamed on a tainted drug has triggered outrage and calls for tighter regulation of the loosely controlled pharmaceutical compounding industry.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.